Article
Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) - 1 Apr 2006
Fujiwara Yoshiro, Kiura Katsuyuki, Toyooka Shinichi, Takigawa Nagio, Tokumo Masaki, Hotta Katsuyuki, Aoe Motoi, Tabata Masahiro, Matsuo Keitaro, Date Hiroshi, Tanimoto Mitsune
Abstract excerpt
PURPOSE: Recent reports have demonstrated that mutation of epidermal growth factor receptor (EGFR) gene is predictive factor for tumor responsiveness to gefitinib suggesting the importance of EGFR status for the treatment of the patients with non-small cell lung cancer (NSCLC). However, the relationship between EGFR mutation and adverse events of gefitinib is still unknown. The aim of this study was to evaluate...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.